Drug Sponsors

Foundation Medicine completes $42.5M Series B financing

Friday, September 21, 2012 12:18 PM

Foundation Medicine, a Cambridge, Mass.-based molecular information company focused on bringing comprehensive cancer genomic analysis to routine clinical care, has completed a $42.5 million Series B financing.

More... »

MacroGenics, Servier to develop three anti-cancer DART products

Friday, September 21, 2012 11:56 AM

MacroGenics, a Rockville, Md.-based privately held biotech that develops next generation antibody therapeutics, and Servier, a privately-held French pharmaceutical company, have entered into an option agreement for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at three undisclosed tumor targets.

More... »

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Boston Scientific to acquire BridgePoint Medical

Thursday, September 20, 2012 07:30 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, agreed to acquire BridgePoint Medical, a privately held company based in Minneapolis, Minn. The transaction is expected to close in the fourth quarter of 2012 subject to customary closing conditions.

More... »

AMRI forms strategic contract with Knopp Biosciences

Wednesday, September 19, 2012 03:18 PM

AMRI, a global contract research and manufacturing organization, has entered into a new strategic agreement with Knopp Biosciences, a Pittsburgh-based drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.  

More... »

Baxter, Onconova form European licensing agreement for anti-cancer compound rigosertib

Wednesday, September 19, 2012 03:11 PM

Baxter International, a developer, manufacturer and marketer of medical products, and Onconova Therapeutics, a discoverer and developer of novel small molecule therapeutics, have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a phase III study for the treatment of a group of rare hematologic malignancies called myelodysplastic syndromes (MDS) and in a phase II/III study for pancreatic cancer.

More... »

CureVac secures $104M in Series D financing

Wednesday, September 19, 2012 12:04 PM

CureVac, a German clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the completion of a $140 million financing round with its main investor, dievini Hopp BioTech Holding.

More... »

Quintiles, Sinclair ink 10-year partnership to commercialize portfolio in Mexico

Wednesday, September 19, 2012 11:37 AM

Quintiles, a fully integrated biopharmaceutical services company, and Sinclair IS Pharma, a topicals and supportive care specialist, have signed a 10-year collaboration and licensing agreement for Quintiles (Rowfarma Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.

More... »

BioFire Diagnostics secures $25M from Athyrium Opportunities Fund

Wednesday, September 19, 2012 10:38 AM

BioFire Diagnostics, a clinical diagnostics company based in Salt Lake City, Utah, has completed a $25 million financing with Athyrium Opportunities Fund, a New York-based fund focusing on investment opportunities in the global healthcare sector

More... »

J&J s to establish innovation centers

Wednesday, September 19, 2012 10:14 AM

Johnson & Johnson is planning to establish four regional innovation centers in major life sciences communities in the world as part of a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across its global healthcare businesses.

More... »